← All diseases
Liver, kidneys and digestion
Liver cirrhosis
Would you like to receive a message when there is new research about Liver cirrhosis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence above each publication explains what was studied — and you'll be notified as soon as new research on Liver cirrhosis is available. View what Premium costs.
Publications and studies (3132)
- New Algorithm Rules Out Acute-on-chronic Liver Failure Development within 28 Days from Acute Decompensation of Cirrhosis. (2023/06/28) ♡
- Trends of Cirrhosis-related Mortality in the USA during the COVID-19 Pandemic. (2023/06/28) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. [Clinical efficacy of entecavir combined with Biejiajian pills and its influence on TCM syndrome scores during the treatment of chronic hepatitis B with hepatic fibrosis and blood stasis syndrome]. (2023/06/20) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report. (2023/06/13) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Systematic Review and Meta-analysis: The Role of Diet in the Development of Nonalcoholic Fatty Liver Disease. (2023/06/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Non-alcoholic fatty liver disease in pregnancy. (2023/06/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The unhealthy lifestyle in primary biliary cholangitis: An enemy to fight. (2023/06/01) ♡
- Natural flavonoids effectively block the CD81 receptor of hepatocytes and inhibit HCV infection: a computational drug development approach. (2023/06/01) ♡
- Bleeding risk after acupuncture in patients taking anticoagulant drugs: A case control study based on real-world data. (2023/06/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Effect and mechanism of Dahuang Zhechong Pills in improving liver aging in rats by regulating ROS-mediated PI3K/Akt/FoxO4 signaling pathway]. (2023/06/01) ♡
- Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. (2023/05/30) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Dahuang Zhechong pill attenuates hepatic sinusoidal capillarization in liver cirrhosis and hepatocellular carcinoma rat model via the MK/integrin signaling pathway. (2023/05/23) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Hyperhomocysteinemia predicts liver-related clinical outcomes in the general population. (2023/05/01) ♡
- The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis. (2023/05/01) ♡
- Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease. (2023/05/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses. (2023/05/01) ♡
- Spleen Stiffness Measurement Across the Spectrum of Liver Disease Patients in Real-World Practice. (2023/05/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Role of Lactoferrin in Treatment of Bile Duct Ligation-Induced Hepatic Fibrosis in Rats: Impact on Inflammation and TGF-β1/Smad2/α SMA Signaling Pathway. (2023/05/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Spur Cell Anaemia in Cirrhosis: A Narrative Review. (2023/05/01) ♡
- The Pattern of Alcohol Use in Alcohol-Related Cirrhosis in Indian Patients: AUDIT Indian Liver Study. (2023/05/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Fibroprogression and Cirrhosis Occurring in Living Liver Donor: First Case Report. (2023/05/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Gallbladder Wall Thickness as a Non-Invasive Marker for Esophageal Varices: A Systematic Review and Meta-Analysis. (2023/05/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report. (2023/04/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The mechanism of peach kernel and safflower herb-pair for the treatment of liver fibrosis based on network pharmacology and molecular docking technology: A review. (2023/04/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A Comprehensive Review of the Pharmacological Importance of Dietary Flavonoids as Hepatoprotective Agents. (2023/04/21) ♡
- HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct Features. (2023/04/17) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review. (2023/04/07) ♡
- Performance of the ADRESS-HCC score in the assessment of the risk of hepatocellular carcinoma in viral cirrhosis in Tunisia. (2023/04/05) ♡
- Prevalence and prognosis of Computed-Tomography defined sarcopenia in Tunisian cirrhotic patients. (2023/04/05) ♡
- Impact of gastric bypass surgery on the liver fibrosis of patients with extreme obesity and nonalcoholic fatty liver disease in 30-month follow-up. (2023/04/01) ♡
- Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study. (2023/04/01) ♡
- Frailty as tested by the Liver Frailty Index in out-patient patients with cirrhosis in China: a cross-sectional study. (2023/04/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Conventional Antibiotics for Spontaneous Bacterial Peritonitis: Are They Still Effective? (2023/04/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway. (2023/04/01) ♡
- CD44-Targeting Drug Delivery System of Exosomes Loading Forsythiaside A Combats Liver Fibrosis via Regulating NLRP3-Mediated Pyroptosis. (2023/04/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial. (2023/04/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Fuzheng Huayu preparation (/) combined with tenofovir disoproxil fumarate on hepatitis B: a systematic review and Meta-analysis. (2023/04/01) ♡
- Cohort Profile: Shiraz Pediatric Liver Cirrhosis Cohort (SPLCCS). (2023/04/01) ♡
- CHRONIC MULTIMORBIDITY OF LOW BACK PAIN OR OTHER CHRONIC BACK DISORDERS IN THE REPUBLIC OF CROATIA. (2023/04/01) ♡
- Exploration of potential mechanism of Rougan formula against hepatic fibrosis by network analysis and experimental assessment. (2023/03/25) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical outcomes associated with complementary and alternative medicine-related "immunity-boosting" practices in patients with cirrhosis during the COVID-19 pandemic - an observational study. (2023/03/24) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics. (2023/03/20) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Evaluation of score parameters for severity assessment of surgery and liver cirrhosis in rats. (2023/03/10) ♡
- Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? (2023/03/09) ♡
- Risk of metabolic syndrome in patients with chronic hepatitis C. (2023/03/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. (2023/03/01) ♡
- Hepatocyte Ninjurin2 promotes hepatic stellate cell activation and liver fibrosis through the IGF1R/EGR1/PDGF-BB signaling pathway. (2023/03/01) ♡
- Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy. (2023/03/01) ♡
- Enzymatically-epoxidized docosahexaenoic acid, 19,20-EpDPE, suppresses hepatic crown-like structure formation and nonalcoholic steatohepatitis fibrosis through GPR120. (2023/03/01) ♡
- Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease. (2023/03/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.